Protara Therapeutics (NASDAQ:TARA – Free Report) had its price target lifted by Oppenheimer from $26.00 to $30.00 in a report released on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.
Separately, HC Wainwright reissued a buy rating and issued a $23.00 price target on shares of Protara Therapeutics in a report on Monday, April 8th.
Check Out Our Latest Research Report on TARA
Protara Therapeutics Stock Performance
Protara Therapeutics (NASDAQ:TARA – Get Free Report) last issued its quarterly earnings data on Wednesday, March 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.13. On average, research analysts predict that Protara Therapeutics will post -3.56 earnings per share for the current year.
About Protara Therapeutics
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.
Featured Articles
- Five stocks we like better than Protara Therapeutics
- How to invest in marijuana stocks in 7 steps
- High-Yield Texas Instruments Could Hit New Highs Soon
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Basic Materials Stocks Investing
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.